Activity of taxane chemotherapy for metastatic breast cancer (MBC) in BRCA1 and BRCA2 mutation carriers compared to sporadic BC patients.

Seynaeve, C.; Jager, Agnes; Hooning, MJ; Deurzen, Carolien Hm van; Bontenbal, M.; Blom, Johannes; Collee, M.; Den, Arnold; Kriege, Mieke

doi:10.1200/jco.2010.28.15_suppl.1020

Cited by 7 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Th e trial presented in the ASCO meeting included 32 patients with BRCA-1 mutation, 19 patients with BRCA-2 mutations and 90 patients not harbouring BRCA mutations as control. Reduced activity of docetaxel in BRCA-1-mutated tumours became evident [40].…”

Section: Chemotherapymentioning

confidence: 99%

Metastatic breast cancer – ASCO 2010

Bartsch

Ziebermayr

2010

memo

View full text Add to dashboard Cite

Background: In the ASCO Annual Meeting, important recent developments in haematology and oncology were presented. In the 2010 ASCO meeting, interest in the fi eld of metastatic breast cancer focused on Poly-(ADP-Ribose)-Polymerase-1 (PARP-1) inhibitors and novel treatment options in Her2-positive disease.Methods: For this review article, authors searched proceedings of the 2010 ASCO Annual Meeting. Abstracts providing important new insights were included and discussed.Results: Results from phase I and II studies of new drugs and novel combinations in Her2-positive disease were presented. Data suggested considerable activity of those therapies upon trastuzumab failure. Much interest focused on the role of PARP-1 inhibitors in triple-negative or BRCA-mutated disease. In those trials, PARP inhibitors were given either alone or in combination with conventional chemotherapy. While a combination of olaparib and paclitaxel produced inacceptable myelotoxicity, a combination of veliparib and temozolomide showed activity in BRCA carriers only. Th e same was true for PARP inhibitors alone: Activity, in general, was limited to patients harbouring BRCA mutations. Further studies evaluated the activity of VEGF and VEGF receptor blockade: While treatment with an anti-VEGF-antibody is active in metastatic breast cancer, the multi-target tyrosine kinase inhibitor sunitinib did not add additional benefi t to chemotherapy in two randomized studies.Conclusion: No praxis changing data were presented in the fi eld of metastatic breast cancer in the ACSO 2010 Annual Meeting. Still, data on PARP-1 inhibitors and new therapies for Her2-positive tumours yielded insights that will eventually lead the path to novel and eff ective treatment options.

show abstract

Section: Chemotherapymentioning

confidence: 99%

Metastatic breast cancer – ASCO 2010

Bartsch

Ziebermayr

2010

memo

View full text Add to dashboard Cite

show abstract

“…The efficacy of taxane monotherapy in gBRCA1/2 mutation metastatic breast cancer has been evaluated in a retrospective case-control study [51]. 32 gBRCA1 and 13 gBRCA2 carriers were matched to 90 controls, with poorer response (Odds ratio [OR]: 25 vs 38% first line; 24 vs 36% ≥ second line; p ≤ 0.001) and poorer disease free survival (2.0 vs 4.7 months; p = 0.03) in gBRCA1 patients.…”

Section: Ovarian Cancermentioning

confidence: 99%

Implications ofBRCA1andBRCA2status for cancer clinical study outcomes

Christie¹,

Cameron²,

Gourley³

2014

Clinical Investigation

View full text Add to dashboard Cite

show abstract

“…Největší studie věnovaná MBC byla studie TNT, kde byly pa cientky s TNBC randomizovány do ramene s CBDCA nebo s docetaxelem; v případě progrese byl povolený crossover. Pa cientky s mutací v genu BRCA1/ 2 dosáhly v rameni s CBDCA vyšší léčebné odpovědi (68 vs. 33 %) a delšího PFS (6,8 vs. 4,4 měsíce), benefit v přežití ale tato studie neprokázala [39]. s mutací v genu BRCA1/ 2.…”

Section: Platinové Deriváty U Metastatického Karcinomu Prsuunclassified

Breast Cancer in BRCA1/2 Mutation Carriers – Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer

Palácová¹

2019

Klin Onkol

View full text Add to dashboard Cite

Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno SouhrnHereditární syndrom karcinomu prsu je spojen s vyšším rizikem vzniku karcinomu prsu a tvoří 5-10 % všech nádorů prsu. Je možné mutace v genech BRCA1/ 2, které jsou reparačními geny, využít cíleně v systémové terapii rozdílné od sporadického karcinomu prsu? Kromě antracyklinů byl prokázán benefit taxanů, především u nádorů s BRCA2 mutací. Výrazný efekt platinových derivátů byl prokázán především u metastatického karcinomu prsu ve studii TNT. Data z neadjuvantních klinických studií u triple negativních nádorů potvrzují větší efekt neadjuvantní chemoterapie ve srovnání se sporadickými nádory, ale efekt karboplatiny nebyl na rozdíl od sporadického karcinomu statisticky signifikantní. Novou léčebnou skupinou, speciálně u nádorů s mutací v genu BRCA1/ 2, jsou PARP inhibitory, u nichž byl prokázán efekt nejenom u triple negativních nádorů, ale i u luminálních nádorů. Klíčová slovakarcinom prsu -mutace BRCA1/ 2 -genomické testy -platinové deriváty -PARP inhibitory SummaryHereditary breast cancer syndrome is associated with a higher risk of develop ing breast cancer and accounts for 5-10% of all breast tumors. Is it possible that mutations in BRCA1/ 2 genes (which are involved in DNA repair genes) should be treated differently from sporadic breast cancer? In addition to anthracyclines, taxanes are effective against tumors with a BRCA2 mutation. A TNT trial showed that platinum derivatives have marked effects against metastatic breast cancer. Data from neoadjuvant trials testing efficacy in triple negative cancer confirm that neoadjuvant chemother apy is more effective against sporadic tumors, whereas the effect of carboplatin is not statistically significant, as opposed to sporadic cancer. A new group of therapeutics, particularly for tumors with mutations in BRCA1/ 2 genes, is PARP inhibitors. These treatments were effective not only against triple negative tumors but also against luminal tumors.

show abstract

Activity of taxane chemotherapy for metastatic breast cancer (MBC) in BRCA1 and BRCA2 mutation carriers compared to sporadic BC patients.

Cited by 7 publications

References 0 publications

Metastatic breast cancer – ASCO 2010

Metastatic breast cancer – ASCO 2010

Implications ofBRCA1andBRCA2status for cancer clinical study outcomes

Breast Cancer in BRCA1/2 Mutation Carriers – Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer

Contact Info

Product

Resources

About